ECSP22027784A - Derivados de 2azaespiro[3.4]octano como agonistas de m4 - Google Patents
Derivados de 2azaespiro[3.4]octano como agonistas de m4Info
- Publication number
- ECSP22027784A ECSP22027784A ECSENADI202227784A ECDI202227784A ECSP22027784A EC SP22027784 A ECSP22027784 A EC SP22027784A EC SENADI202227784 A ECSENADI202227784 A EC SENADI202227784A EC DI202227784 A ECDI202227784 A EC DI202227784A EC SP22027784 A ECSP22027784 A EC SP22027784A
- Authority
- EC
- Ecuador
- Prior art keywords
- agonists
- 2azaspire
- octane derivatives
- formula
- octane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
En el presente documento se proporcionan compuestos de acuerdo con la Fórmula (I) o su sal farmacéuticamente aceptable, en donde R1, R2, R3, R5, y R7 se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962912986P | 2019-10-09 | 2019-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22027784A true ECSP22027784A (es) | 2022-05-31 |
Family
ID=72944206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202227784A ECSP22027784A (es) | 2019-10-09 | 2022-04-07 | Derivados de 2azaespiro[3.4]octano como agonistas de m4 |
Country Status (20)
Country | Link |
---|---|
US (3) | US11485742B2 (es) |
EP (1) | EP4041737A1 (es) |
JP (1) | JP7349567B2 (es) |
KR (1) | KR20220079608A (es) |
CN (1) | CN114555606A (es) |
AR (1) | AR120169A1 (es) |
AU (1) | AU2020364186B2 (es) |
CA (1) | CA3155589A1 (es) |
CL (1) | CL2022000892A1 (es) |
CO (1) | CO2022004391A2 (es) |
CR (1) | CR20220153A (es) |
EC (1) | ECSP22027784A (es) |
IL (1) | IL291600A (es) |
JO (1) | JOP20220084A1 (es) |
MX (1) | MX2022004215A (es) |
PE (1) | PE20221454A1 (es) |
TW (1) | TW202128703A (es) |
UY (1) | UY38907A (es) |
WO (1) | WO2021070091A1 (es) |
ZA (1) | ZA202202913B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3156320A1 (en) * | 2019-10-09 | 2021-04-15 | Novartis Ag | 2-AZASPIRO[3,4] OCTANE DERIVATIVES USED AS M4 AGONISTS |
WO2024059249A1 (en) * | 2022-09-16 | 2024-03-21 | Cerevel Therapeutics, Llc | M4 activators/modulators and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276520A1 (en) | 2002-11-13 | 2006-12-07 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
WO2006006490A1 (ja) | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
JP2008521821A (ja) | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
CA2661503A1 (en) | 2006-08-25 | 2008-02-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11.beta. -hydroxysteroid dehydrogenase type 1 |
US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
EP2344457A1 (en) | 2008-10-29 | 2011-07-20 | Grünenthal GmbH | Substituted spiroamines |
BRPI1007350B8 (pt) * | 2009-01-26 | 2021-05-25 | Israel Institute For Biological Res | compostos espiro heterocíclicos bicíclicos |
WO2012062752A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | RADIOLABELLED mGLuR2 PET LIGANDS |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
CA2842841C (en) | 2011-07-27 | 2016-04-19 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as protein kinase inhibitors |
WO2014039489A1 (en) | 2012-09-07 | 2014-03-13 | Zoetis Llc | Spirocyclic derivatives as antiparasitic agents |
DK2897948T3 (en) | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
EP3406609A1 (en) * | 2014-02-06 | 2018-11-28 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic receptor agonists |
NZ731118A (en) | 2014-10-31 | 2023-05-26 | Indivior Uk Ltd | Dopamine d3 receptor antagonists compounds |
GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB2540998A (en) | 2015-08-04 | 2017-02-08 | Phagenesis Ltd | Catheter |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CA3024180A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
TWI801540B (zh) | 2018-03-23 | 2023-05-11 | 美商輝瑞大藥廠 | 哌嗪氮雜螺衍生物 |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
-
2020
- 2020-10-07 EP EP20793461.3A patent/EP4041737A1/en active Pending
- 2020-10-07 JP JP2022520844A patent/JP7349567B2/ja active Active
- 2020-10-07 CR CR20220153A patent/CR20220153A/es unknown
- 2020-10-07 WO PCT/IB2020/059431 patent/WO2021070091A1/en active Application Filing
- 2020-10-07 US US17/065,367 patent/US11485742B2/en active Active
- 2020-10-07 AR ARP200102774A patent/AR120169A1/es unknown
- 2020-10-07 AU AU2020364186A patent/AU2020364186B2/en active Active
- 2020-10-07 JO JOP/2022/0084A patent/JOP20220084A1/ar unknown
- 2020-10-07 CA CA3155589A patent/CA3155589A1/en active Pending
- 2020-10-07 TW TW109134712A patent/TW202128703A/zh unknown
- 2020-10-07 PE PE2022000586A patent/PE20221454A1/es unknown
- 2020-10-07 KR KR1020227015112A patent/KR20220079608A/ko unknown
- 2020-10-07 CN CN202080070235.1A patent/CN114555606A/zh active Pending
- 2020-10-07 UY UY0001038907A patent/UY38907A/es unknown
- 2020-10-07 MX MX2022004215A patent/MX2022004215A/es unknown
-
2022
- 2022-03-10 ZA ZA2022/02913A patent/ZA202202913B/en unknown
- 2022-03-22 IL IL291600A patent/IL291600A/en unknown
- 2022-04-06 CO CONC2022/0004391A patent/CO2022004391A2/es unknown
- 2022-04-07 CL CL2022000892A patent/CL2022000892A1/es unknown
- 2022-04-07 EC ECSENADI202227784A patent/ECSP22027784A/es unknown
- 2022-08-08 US US17/818,321 patent/US11820778B2/en active Active
-
2023
- 2023-10-30 US US18/497,296 patent/US20240140959A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020364186A1 (en) | 2022-04-21 |
MX2022004215A (es) | 2022-05-03 |
US20220411435A1 (en) | 2022-12-29 |
US20240140959A1 (en) | 2024-05-02 |
US11820778B2 (en) | 2023-11-21 |
ZA202202913B (en) | 2023-06-28 |
CL2022000892A1 (es) | 2023-01-20 |
CO2022004391A2 (es) | 2022-04-29 |
KR20220079608A (ko) | 2022-06-13 |
AU2020364186B2 (en) | 2023-11-30 |
US11485742B2 (en) | 2022-11-01 |
CA3155589A1 (en) | 2021-04-15 |
JOP20220084A1 (ar) | 2023-01-30 |
CN114555606A (zh) | 2022-05-27 |
IL291600A (en) | 2022-05-01 |
WO2021070091A1 (en) | 2021-04-15 |
CR20220153A (es) | 2022-05-03 |
UY38907A (es) | 2021-05-31 |
US20210130365A1 (en) | 2021-05-06 |
PE20221454A1 (es) | 2022-09-21 |
JP7349567B2 (ja) | 2023-09-22 |
TW202128703A (zh) | 2021-08-01 |
JP2022551853A (ja) | 2022-12-14 |
EP4041737A1 (en) | 2022-08-17 |
AR120169A1 (es) | 2022-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
CO2018004800A2 (es) | Antagonistas del receptor muscarinico 4 y metodos de uso. | |
MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
PH12021550049A1 (en) | Selective estrogen receptor degraders. | |
CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
CL2020001817A1 (es) | Moduladores del receptor c5a | |
MY197742A (en) | Morphinan derivative | |
MY197561A (en) | Composition for increasing expression of pgc-1? | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
PH12020551342A1 (en) | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | |
AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
PE20201148A1 (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
EA201992804A1 (ru) | Производные аминогликозида и их применение при лечении генетических заболеваний | |
CL2021003348A1 (es) | Derivados de piridin–3–ilo. | |
AR107310A1 (es) | Inhibidores de tetrahidrocarbazol de receptores sirt1 | |
BR112022006157A2 (pt) | Derivados de 5-oxa-2-azaespiro[3.4]octano como agonistas de m4 |